BackInternational Stem Cell Overview
International Stem Cell Corporation

International Stem Cell P/E Ratio

International Stem Cell (ISCO) has a P/E ratio of -2.55, below the Healthcare sector average of 21.65.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-2.55

P/E Ratio

-2.55

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

International Stem Cell (ISCO) FAQ

International Stem Cell (ISCO) currently reports a P/E ratio of -2.55. That is below the Healthcare sector average of 21.65. Use the charts on this page to explore International Stem Cell's P/E ratio history and peer comparisons.

International Stem Cell's P/E ratio of -2.55 is lower than the Healthcare sector average of 21.65. That is roughly 111.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates International Stem Cell's market price to a fundamental measure such as earnings, sales, or book value. At -2.55, ISCO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -2.55, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.65. From there, open related valuation or income-statement pages for International Stem Cell, and consider following ISCO for alerts when major investors trade the stock.

International Stem Cell is classified in the Healthcare sector. On P/E ratio, it currently shows -2.55 versus a sector average near 21.65. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ISCO with unrelated industries.